Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); Awaiting Approval of HIV-OTC Test
Tweet
Share
E-mailGet Alerts OSUR Hot Sheet
Price: $3.88 +3.74%
Rating Summary:
9 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
9 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on OraSure Technologies (NASDAQ: OSUR) price target of $14.00.
Analyst, Jeffrey Frelick, said, "Near--term approval likely for HIV--OTC. For a product that moved slowly through the early years of development, it has suddenly advanced rapidly in the past nine to 12 months. Based on the 180-day PMA clock that has been ticking since early January when OSUR filed, FDA approval could come as early as July 7; however, we think late summer is more likely."
For an analyst ratings summary and ratings history on OraSure Technologies click here. For more ratings news on OraSure Technologies click here.
Shares of OraSure Technologies closed at $10.32 yesterday.
Analyst, Jeffrey Frelick, said, "Near--term approval likely for HIV--OTC. For a product that moved slowly through the early years of development, it has suddenly advanced rapidly in the past nine to 12 months. Based on the 180-day PMA clock that has been ticking since early January when OSUR filed, FDA approval could come as early as July 7; however, we think late summer is more likely."
For an analyst ratings summary and ratings history on OraSure Technologies click here. For more ratings news on OraSure Technologies click here.
Shares of OraSure Technologies closed at $10.32 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Cummins (CMI) PT Lowered to $675 at Jefferies
- Rockwell Automation (ROK) PT Lowered to $490 at DA Davidson
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
